STERIS (NYSE:STE) Releases Quarterly Earnings Results

STERIS (NYSE:STE) released its quarterly earnings results on Tuesday. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.16, RTT News reports. STERIS had a return on equity of 13.89% and a net margin of 7.36%. The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.27 billion. During the same quarter last year, the firm posted $2.00 EPS. The company’s revenue was down .4% compared to the same quarter last year. STERIS updated its FY25 guidance to $9.05-$9.25 EPS and its FY 2025 guidance to 9.050-9.250 EPS.

STERIS Trading Down 1.5 %

STERIS stock traded down $3.70 during trading hours on Friday, reaching $235.98. The company had a trading volume of 421,762 shares, compared to its average volume of 488,756. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.08 and a quick ratio of 2.36. The company has a 50-day moving average price of $225.17 and a 200 day moving average price of $222.88. The firm has a market cap of $23.33 billion, a price-to-earnings ratio of 61.76 and a beta of 0.83. STERIS has a 12-month low of $195.47 and a 12-month high of $243.37.

STERIS Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be paid a $0.57 dividend. This is a boost from STERIS’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date of this dividend is Thursday, September 5th. STERIS’s payout ratio is 54.45%.

Insiders Place Their Bets

In other STERIS news, SVP Cary L. Majors sold 2,024 shares of STERIS stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $232.13, for a total value of $469,831.12. Following the transaction, the senior vice president now directly owns 11,369 shares of the company’s stock, valued at approximately $2,639,085.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Renato Tamaro sold 1,154 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $231.64, for a total transaction of $267,312.56. Following the transaction, the vice president now directly owns 6,677 shares of the company’s stock, valued at $1,546,660.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Cary L. Majors sold 2,024 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $232.13, for a total value of $469,831.12. Following the transaction, the senior vice president now directly owns 11,369 shares in the company, valued at $2,639,085.97. The disclosure for this sale can be found here. Insiders have sold 7,762 shares of company stock valued at $1,798,477 in the last ninety days. Company insiders own 1.14% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on STE shares. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Thursday. JMP Securities reiterated a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research report on Wednesday. Piper Sandler reiterated a “neutral” rating and set a $225.00 price objective (up from $220.00) on shares of STERIS in a research report on Friday, May 10th. StockNews.com lowered STERIS from a “buy” rating to a “hold” rating in a research report on Monday. Finally, Stephens reiterated an “overweight” rating and set a $260.00 price objective on shares of STERIS in a research report on Wednesday. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $243.60.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.